Page last updated: 2024-10-29

staurosporine aglycone and Triple Negative Breast Neoplasms

staurosporine aglycone has been researched along with Triple Negative Breast Neoplasms in 1 studies

staurosporine aglycone: metabolite from culture broth of Nocardiopsis sp.; a neurotrophin antag; inhibits BDNF TrkB receptor

Triple Negative Breast Neoplasms: Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Strietz, J1
Stepputtis, SS1
Preca, BT1
Vannier, C1
Kim, MM1
Castro, DJ1
Au, Q1
Boerries, M1
Busch, H1
Aza-Blanc, P1
Heynen-Genel, S1
Bronsert, P1
Kuster, B1
Stickeler, E1
Brabletz, T1
Oshima, RG1
Maurer, J1

Other Studies

1 other study available for staurosporine aglycone and Triple Negative Breast Neoplasms

ArticleYear
ERN1 and ALPK1 inhibit differentiation of bi-potential tumor-initiating cells in human breast cancer.
    Oncotarget, 2016, Dec-13, Volume: 7, Issue:50

    Topics: Animals; Antineoplastic Agents; Carbazoles; Caseins; Cell Differentiation; Cell Line, Tumor; Cell Pr

2016